Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968159 · ClinicalTrials.gov registry record · Phase 3
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT03968159: Completed Phase 3 study, sponsored by ACADIA Pharmaceuticals.
NCT03968159 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 298 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03968159, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
Primary Outcome
The HAMD-17 consists of 8 items with a score on a 3 point scale and 9 items with a score on a 5 point scale. The total score ranging from 0 to 52 will be calculated as the sum of the scores for all 17 items. Higher total scores denote more severe depression.
Interventions
- DRUG Placebo
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2020-05-29 |
| Phase | Phase 3 |
What the finished NCT03968159 record still lists
NCT03968159 is an interventional study that assigns participants to a tested intervention. The registered 298 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03968159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03968159 about?
NCT03968159 is a clinical study titled "Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment". To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
What is the current status of trial NCT03968159?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2019-04-25. Estimated completion is 2020-05-29.
What interventions are being tested in trial NCT03968159?
The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03968159?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03968159's enrollment target sits among peer trials
298 1162nd of 2000 higher than 838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
- NCT06780111 · 298 participants · Phase 1
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- NCT07209358 · 298 participants · NA
EDX110 Randomized Control Trial for Treatment of DFUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI